Baudax Bio Inc Ordinary Shares Stock (OTC: BXRX)

Baudax Bio Inc Ordinary Shares Stock (OTC:BXRX), Trade Ideas

Baudax Bio

Baudax Bio Inc Ordinary Shares

Baudax Bio Inc

With the highly anticipated Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) halving just two days away, analysts crypto research firm 10x Research are offering a detailed breakdown of what investors can expect in the <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38314438/jpmorgan-bitcoin-price-may-drop-after-halving-despite-miner-shakeup">aftermath of this pivotal event</a>.
What Happened: &#8220;While social media is abuzz with predictions of an immediate price surge,&#8221; <a href="https://mail.10xresearch.co/p/happens-bitcoin-halving?utm_source=mail.10xresearch.co&amp;utm_medium=newsletter&amp;utm_campaign=what-happens-after-the-bitcoin-halving">says</a> Markus Thielen, an analyst at 10x Research, &#8220;our analysis suggests a more nuanced scenario.&#8221;
Pre-Halving Frenzy May Not Translate To Post-Halving Boom
Thielen highlights Google Trends data showing a surge in &#8220;Bitcoin Halving&#8221; searches, exceeding even the 2020 halving peak. 
However, he cautions against relying solely on historical price movements.
&#8220;We believe Bitcoin&#8217;s price movements are driven by deeper economic incentives,&#8221; says Thielen. 
&#8220;While previous halvings were followed by price increases, the average return has diminished over time.&#8221;
Short-Term Volatility, Long-Term Potential
Based on analysis of past halving cycles, 10x Research predicts a period of potential consolidation following the initial hype. 
Their analysis points to several key factors:
<ul>
<li>Miner Inventory Liquidation:&nbsp;Miners, facing a 50% reduction in block rewards, may need to sell a significant portion of their Bitcoin holdings to maintain revenue. This could create downward pressure on the price in the short term.</li>
<li>Shifting Supply Dynamics:&nbsp;Pre-halving, miners may restrict supply to inflate prices. However, post-halving, they are likely to increase sales to offset the reward reduction.</li>
<li>Macroeconomic Headwinds: Rising interest rates and a potential economic slowdown could further impact market sentiment.</li>
</ul>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38313318/coinbase-veteran-nana-murugesan-joins-matter-labs-to-scale-zksync">Coinbase Veteran Nana Murugesan Joins Matter Labs To Scale zkSync</a>
A Look Back At 2020: Patience May Be Key
Thielen points to the 2020 halving as an example. 
While Bitcoin experienced a modest price increase initially, the significant rally only began months later. 
Similarly, mining stocks initially lagged but surged later in the year.
&#8220;This highlights the importance of a long-term perspective,&#8221; says Thielen. 
&#8220;The halving is a fundamental event that shapes Bitcoin&#8217;s future, but it&#8217;s just one piece of the puzzle. Other factors will also play a role in determining its price trajectory.&#8221;
Gaining Deeper Insights At Benzinga&#8217;s Future Of Digital Assets
For a deeper dive into the post-halving market dynamics and investment strategies, consider attending Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> conference on Nov. 19. 
This event will feature industry leaders and experts discussing the latest trends in on-chain analysis, investment strategies, and <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38294295/u-s-senators-lummis-gillibrand-renew-push-for-stablecoin-bill">regulatory developments in the digital asset space.</a>
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38312737/bitcoin-defies-165m-etf-outflows-bounces-above-62-000">Bitcoin Defies $165M ETF Outflows, Bounces Above $62,000</a>
Image created using artificial intelligence with Midjourney.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

$BTC

What Happens After The Bitcoin Halving?

Discover Financial Services&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) shares are&nbsp;<a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Thursday.&nbsp;</a>
The company reported first-quarter revenue of $4.21 billion, net of interest expense, which was up 13% year-over-year. The total beat a Street estimate of $4.07 billion, according to<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348" rel="noreferrer noopener">&nbsp;data from Benzinga Pro.</a>
Read More:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38302779/discover-financial-q1-earnings-highlights-revenue-beat-charge-offs-rise-merger-update-and-more" rel="noreferrer noopener">Discover Financial Q1 Earnings Highlights: Revenue Beat, Charge-Offs Rise, Merger Update And More</a>
Goldman Sachs&nbsp;analyst Ryan M. Nash highlights the company&#8217;s whopping $799 million charge related to the card misclassification remediation reserve in the quarter, which Discover Financial Services has incurred in the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">quarter under review.</a>
In terms of credit, March metrics showed signs of improvement, with card DQs down -18bps month on month, outperforming seasonality by 12 bps while the year-over-year increase fell to +107bps versus +127bps last month (+135bps in Jan), the analyst notes.
Evercore&nbsp;ISI&nbsp;analyst John Pancari also flags Discover Financial Services&#8217; sizable incremental customer remediation reserve.
According to the analyst, this is in addition to the company&#8217;s existing ~$370 million reserve related to the card misclassification/merchant tiering issue.&nbsp;
Pancari reiterated an In Line rating on the stock, with&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/DFS/analyst-ratings" rel="noreferrer noopener">price forecast of $140.</a>
Wells Fargo&nbsp;analyst Donald Fandetti reiterated an Equal Weight rating on Discover Financial Services with a forecast of $135.
While Fandetti applauds the company&#8217;s core beat, he cautions about the company&#8217;s &#8220;large&#8221; remediation reserve.
Overall, an ~10.8x P/E is warranted given the optionality of the pending&nbsp;Capital One Financial Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) acquisition, partially mitigated by the deal regulatory&nbsp;<a target="_blank" href="https://www.benzinga.com//node/37204398" rel="noreferrer noopener">challenges and uncertain macro.&nbsp;</a>
The 10.8x is above the historical ~9-10x for card issuers, the analyst highlights.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38310059/looking-for-affordable-connectivity-and-streaming-comcast-unveils-now-eyes-prepaid-and-month-to-" rel="noreferrer noopener">Looking For Affordable Connectivity And Streaming? Comcast Unveils NOW &#8211; Eyes Prepaid And Month-to-month Internet</a>
Price Action: DFS shares are trading higher by 3.25% to $123.82 on the last check Thursday. 
Photo via Shutterstock

Analyst Color

Equities

Price Target

Reiteration

Analyst Ratings

Movers

Trading Ideas

General

Discover Financial Faces Concerns Over Remediation Reserve, Analysts Caution Despite Q1 Sales Growth

Investors with a lot of money to spend have taken a bullish stance on Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DVN, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Devon Energy.
This isn't normal.
The overall sentiment of these big-money traders is split between 60% bullish and 40%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $283,973, and 7 are calls, for a total amount of $334,945.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $30.0 to $57.5 for Devon Energy during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Devon Energy's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Devon Energy's whale trades within a strike price range from $30.0 to $57.5 in the last 30 days. 
<h3>Devon Energy 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713464288_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$4.0</td>
<td>$3.2</td>
<td>$3.37</td>
<td>$55.00</td>
<td>$147.9K</td>
<td>74</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.45</td>
<td>$5.35</td>
<td>$5.35</td>
<td>$50.00</td>
<td>$110.7K</td>
<td>1.0K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$5.95</td>
<td>$5.85</td>
<td>$5.88</td>
<td>$57.50</td>
<td>$101.8K</td>
<td>280</td>
<td style="text-align: right;">94</td>
</tr>
<tr>
<td>DVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$3.95</td>
<td>$3.9</td>
<td>$3.9</td>
<td>$55.00</td>
<td>$47.1K</td>
<td>8.3K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>DVN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/26/24</td>
<td>$21.8</td>
<td>$21.55</td>
<td>$21.8</td>
<td>$30.00</td>
<td>$43.6K</td>
<td>10</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About Devon Energy</h3>
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2023, net production totaled roughly 658 thousand boe/d, of which oil and natural gas liquids made up roughly three-quarters of production, with natural gas accounting for the remainder.
After a thorough review of the options trading surrounding Devon Energy, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Devon Energy</h3>
<ul>
<li>Currently trading with a volume of 2,517,916, the DVN's price is up by 0.25%, now at $51.8. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 13 days.</li>
</ul>
<h3>What Analysts Are Saying About Devon Energy</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $59.0.
<ul>
<li>An analyst from Citigroup has decided to maintain their Buy rating on Devon Energy, which currently sits at a price target of $62. </li>
<li>Maintaining their stance, an analyst from UBS continues to hold a Neutral rating for Devon Energy, targeting a price of $57. </li>
<li>In a cautious move, an analyst from Barclays downgraded its rating to Equal-Weight, setting a price target of $59. </li>
<li>Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Devon Energy with a target price of $50. </li>
<li>An analyst from Scotiabank has decided to maintain their Sector Outperform rating on Devon Energy, which currently sits at a price target of $67. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Devon Energy with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Markets

A Closer Look at Devon Energy's Options Market Dynamics

Investors with a lot of money to spend have taken a bearish stance on Phillips 66 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSX#NYSE">PSX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with PSX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 8 uncommon options trades for Phillips 66.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 62%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $71,640, and 6 are calls, for a total amount of $707,495.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $85.0 to $175.0 for Phillips 66 over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Phillips 66 stands at 235.25, with a total volume reaching 360.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Phillips 66, situated within the strike price corridor from $85.0 to $175.0, throughout the last 30 days.
<h3>Phillips 66 Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713464283_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$11.8</td>
<td>$11.5</td>
<td>$11.5</td>
<td>$150.00</td>
<td>$296.7K</td>
<td style="text-align: right;">163</td>
<td style="text-align: right;">294</td>
</tr>
<tr>
<td>PSX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/19/24</td>
<td>$9.8</td>
<td>$9.2</td>
<td>$9.5</td>
<td>$145.00</td>
<td>$272.6K</td>
<td style="text-align: right;">773</td>
<td style="text-align: right;">14</td>
</tr>
<tr>
<td>PSX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$17.1</td>
<td>$16.8</td>
<td>$17.0</td>
<td>$160.00</td>
<td>$44.2K</td>
<td style="text-align: right;">14</td>
<td style="text-align: right;">21</td>
</tr>
<tr>
<td>PSX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$3.7</td>
<td>$3.6</td>
<td>$3.7</td>
<td>$175.00</td>
<td>$37.0K</td>
<td style="text-align: right;">309</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>PSX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$73.2</td>
<td>$69.7</td>
<td>$71.1</td>
<td>$85.00</td>
<td>$35.5K</td>
<td style="text-align: right;">63</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About Phillips 66</h3>
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 1.8 million barrels per day, or mmb/d. In 2023, the Rodeo, California, facility ceased operations and be converted to produce renewable diesel. The midstream segment comprises extensive transportation and NGL processing assets and includes DCP Midstream, which holds 600 mbd of NGL fractionation and 22,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Having examined the options trading patterns of Phillips 66, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Phillips 66's Current Market Status</h3>
<ul>
<li>With a volume of 1,239,930, the price of PSX is down 0.0% at $157.25. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 8 days.</li>
</ul>
<h3>Professional Analyst Ratings for Phillips 66</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $166.2.
<ul>
<li>Consistent in their evaluation, an analyst from Goldman Sachs keeps a Buy rating on Phillips 66 with a target price of $174. </li>
<li>An analyst from Wells Fargo has decided to maintain their Overweight rating on Phillips 66, which currently sits at a price target of $179. </li>
<li>Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Outperform rating for Phillips 66, targeting a price of $156. </li>
<li>Consistent in their evaluation, an analyst from Mizuho keeps a Neutral rating on Phillips 66 with a target price of $167. </li>
<li>An analyst from Barclays persists with their Equal-Weight rating on Phillips 66, maintaining a target price of $155. </li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Phillips 66 with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Phillips 66 Unusual Options Activity

Financial giants have made a conspicuous bearish move on Home Depot. Our analysis of options history for Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) revealed 16 unusual trades.
Delving into the details, we found 12% of traders were bullish, while 87% showed bearish tendencies. Out of all the trades we spotted, 10 were puts, with a value of $595,315, and 6 were calls, valued at $399,057.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $300.0 to $395.0 for Home Depot during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Home Depot's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Home Depot's whale trades within a strike price range from $300.0 to $395.0 in the last 30 days. 
<h3>Home Depot Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713464278_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$6.1</td>
<td>$5.95</td>
<td>$6.1</td>
<td>$345.00</td>
<td>$183.0K</td>
<td style="text-align: right;">690</td>
<td style="text-align: right;">313</td>
</tr>
<tr>
<td>HD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$18.85</td>
<td>$18.85</td>
<td>$18.85</td>
<td>$345.00</td>
<td>$93.9K</td>
<td style="text-align: right;">606</td>
<td style="text-align: right;">152</td>
</tr>
<tr>
<td>HD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$18.85</td>
<td>$18.55</td>
<td>$18.55</td>
<td>$345.00</td>
<td>$92.7K</td>
<td style="text-align: right;">606</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>HD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/21/24</td>
<td>$18.85</td>
<td>$16.5</td>
<td>$17.55</td>
<td>$345.00</td>
<td>$87.7K</td>
<td style="text-align: right;">606</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>HD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$38.95</td>
<td>$37.75</td>
<td>$38.0</td>
<td>$300.00</td>
<td>$60.8K</td>
<td style="text-align: right;">667</td>
<td style="text-align: right;">2</td>
</tr>
</tbody>
</table>

<h3>About Home Depot</h3>
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). Moreover, the additions of the Company Store brought textile exposure to the lineup, while Redi Carpet added multifamily flooring.
After a thorough review of the options trading surrounding Home Depot, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of Home Depot</h3>
<ul>
<li>With a volume of 1,565,096, the price of HD is up 0.01% at $332.87. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 26 days.</li>
</ul>
<h3>What Analysts Are Saying About Home Depot</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $385.0.
<ul>
<li>An analyst from Truist Securities has decided to maintain their Buy rating on Home Depot, which currently sits at a price target of $417. </li>
<li>Consistent in their evaluation, an analyst from Evercore ISI Group keeps a Outperform rating on Home Depot with a target price of $415. </li>
<li>Maintaining their stance, an analyst from Telsey Advisory Group continues to hold a Market Perform rating for Home Depot, targeting a price of $360. </li>
<li>An analyst from Wedbush persists with their Outperform rating on Home Depot, maintaining a target price of $410. </li>
<li>Reflecting concerns, an analyst from HSBC lowers its rating to Reduce with a new price target of $323.</li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Home Depot, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Home Depot's Options Frenzy: What You Need to Know

The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Motorcar Parts of America, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPAA#NASDAQ">MPAA</a>)</h3>
<ul>
<li>On Feb. 9, Motorcar Parts of America posted downbeat quarterly results. The company's stock fell around 29% over the past month and has a <a href="https://www.benzinga.com/quote/MPAA">52-week low of $4.26</a>.</li>
<li>RSI Value: 21.74</li>
<li>MPAA Price Action: Shares of Motorcar Parts of America gained 3.9% to trade at $5.31 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">Malibu Boats, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBUU#NASDAQ">MBUU</a>)   </h3>
<ul>
<li>On April 15, Raymond James analyst Joseph Altobello downgraded Malibu Boats from Outperform to Market Perform. The company's stock fell around 16% over the past five days. It <a href="https://www.benzinga.com/quote/MBUU">has a 52-week low</a> of $33.82.</li>
<li>RSI Value: 26.13</li>
<li>MBUU Price Action: Shares of Malibu Boats rose 1% to trade at $34.30 on Thursday.</li>
</ul>
<h3 class="wp-block-heading">ThredUp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDUP#NASDAQ">TDUP</a>)</h3>
<ul>
<li>On March 4, ThredUp reported worse-than-expected fourth-quarter GAAP EPS results.. The company's stock fell around 11% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/TDUP">low of $1.5150</a>.</li>
<li>RSI Value: 29.49</li>
<li>TDUP Price Action: Shares of ThredUp rose 0.7% to trade at $1.54 on Thursday.</li>
</ul>

Read More: <a href="https://www.benzinga.com/news/24/04/38316287/netflix-earnings-are-imminent-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call">Netflix Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call</a>

Long Ideas

Intraday Update

MBUU

MPAA

TDUP

Top 3 Consumer Stocks Which Could Rescue Your Portfolio This Quarter

SkyBridge Capital's Anthony Scaramucci believes the upcoming Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) halving could put the world&#8217;s largest crypto on a<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38065857/crypto-analyst-believes-200k-for-bitcoin-would-be-underwhelming-predicts-king-crypto-to-re"> path towards $200,000 per coin</a>.
What To Know: Thursday on CNBC&#8217;s &#8220;Squawk Box,&#8221; Scaramucci suggested that Bitcoin could soon break through new highs. He expects the crypto to trend higher over the next 12 months.
&#8220;Long term, with the halving coming this week &#8230; I think this thing trades to $170,000, possibly to $200,000,&#8221; Scaramucci said. 
<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38293678/spot-bitcoin-etfs-bleed-another-58m-mining-stocks-under-pressure">Bitcoin miners</a> receive a reward for successfully mining transactions. The amount of rewards miners receive is set to be cut in half in the coming days. Crypto markets have historically rallied in the months following a halving event.
Related Link: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38317307/bitcoin-halving-will-institutions-and-smart-money-upend-past-price-rallies">Bitcoin Halving: Will Institutions And &#8220;Smart Money&#8221; Upend Past Price Rallies?</a>
Scaramucci told CNBC the current downside risk in Bitcoin is about 10% to 15%, given geopolitical uncertainty, but the upside is significantly higher, he said, citing heavy demand due to recently approved Bitcoin ETFs and new players coming into the space.
Scaramucci previously pointed out that <a href="https://www.benzinga.com/markets/cryptocurrency/24/02/37370160/this-upcoming-catalyst-could-ignite-bitcoin-rally-to-200k-per-coin">Bitcoin tends to quadruple</a> after a halving. Although Bitcoin is 14 years old, it&#8217;s still very young in terms of adoption, he said. Until Bitcoin reaches 1 billion users, the asset will remain very volatile, he added. 
&#8220;Over a rolling four-year period of time, no one has ever lost money in Bitcoin. If you&#8217;re willing to hold the asset for say five years &#8230; I think you do very well,&#8221; Scaramucci said. 
If you are willing to hold the asset even longer, you could be in for some ridiculous gains, per Scaramucci&#8217;s longer-term view. He told CNBC he expects Bitcoin to eventually eclipse the market cap of gold, which is currently estimated at around $16 trillion. Bitcoin&#8217;s current market cap is approximately $1.25 trillion.
&#8220;The acceptance regulatorily is going to allow people to put it in the portfolio. A 1% position in these global portfolios takes it there,&#8221; Scaramucci said.
See Also: &#8216;<a href="https://www.benzinga.com/news/24/04/38286236/once-trumper-scaramucci-warns-re-electing-ex-president-would-result-in-american-fascism-and-be-very">Once-Trumper&#8217; Scaramucci Warns Re-Electing Ex-President Would Result In &#8216;American Fascism&#8217; And Be &#8216;Very Bad&#8217; For Business: &#8216;He Wants To Be North American Autocrat&#8217;</a>
$BTC Price Action: Bitcoin was up 5.27% over a 24-hour period, hovering around $63,400 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Photo: Shutterstock.

Commodities

Bitcoin To $200K After Halving? SkyBridge's Scaramucci Believes The Crypto Will Eclipse Gold Market Cap

With the <a href="https://www.benzinga.com/topic/bitcoin-halving">Bitcoin halving</a> around the corner, Benzinga takes a look at how the meme coin landscape has changed since the last halving.
What Happened: According to CoinGecko <a href="https://www.coingecko.com/en/categories/meme-token">data</a>, the market capitalization of meme coins stands around $49.3 billion.
While countless meme coins are being launched on a daily basis, the top two players have remained unchanged since the last halving:
<ul>
<li>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>): Launched in December 2013, the meme coin leader has erased multiple zeros from its price, currently trading at $0.15, up 60% year-to-date. It is ranked eighth on the overall crypto board. Here is <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38190312/what-happened-to-dogecoin-after-the-bitcoin-halving-four-years-ago">what happened to Dogecoin after the last Bitcoin Halving.</a></li>
<li>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>):  Introduced as the &#8220;Dogecoin Killer,&#8221; Shiba Inu launched in August 2020, a few months after the last halving. Currently ranked second on the board, Shiba Inu is famously volatile, up 96% year-to-date and ranked eleventh among all cryptocurrencies.</li>
</ul>
The meme coin leaders may not have real-world utilities, but Shiba Inu has been consistently working on developing its token&#8217;s applicability and adopting token burns to reduce market supply and impact price movements. Meanwhile, the Dogecoin community is eagerly awaiting the coin&#8217;s adoption as a payment feature on X.       
Heavily-followed crypto trader Crypto Tony <a href="https://twitter.com/CryptoTony__/status/1780527118343942496">tweeted</a>, "Memecoins really are ride to 0 or to the moon. Always enter expecting nothing back."         
Next in line are the $2 billion valuation meme coin club members:
<ul>
<li>Dogwifhat (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>): Introduced in December 2023 as a Shiba Inu dog wearing a hat, this meme coin has shot from zero to over $4 billion in the past six months. It reached the $1 mark within three months of its launch and quickly hit subsequent price thresholds up to nearly $5, outpacing the meme coin leaders that have yet to reach the $1 level.</li>
<li>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>): Launched in April 2023, this frog-themed coin stands out among the dog and cat coins. Not only has it been recently listed on leading exchanges, but it is also witnessing a significant increase in its holder base.</li>
</ul>
Following Shiba Inu&#8217;s lead in burning tokens as a marketing gimmick are:
<ul>
<li>Floki (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">FLOKI</a>), launched in July 2021, and Bonk (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BONK</a>), introduced in January 2023, have accumulated 275% and 1,450% gains respectively in the past year. Floki has burned around 59% of its total supply to date, while BONKBot revealed in an early April tweet that it has burned 256.8 billion BONK tokens so far.</li>
</ul>
Next is a community-driven AI project:
<ul>
<li>CorgiAI (CRYPTO: CORGIAI): Launched in July 2023, this token aims to expand and become the top community token in the Cronos ecosystem and beyond. It has seen a 563% gain in the past year, rapidly reaching its position in the top 10 meme coins.</li>
</ul>
The latest entrants in 2024 are:
<ul>
<li>Brett (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BRETT</a>), Book Of Meme (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">BOME</a>), and Cat in a Dogs World (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">MEW</a>) are the latest additions to the meme coin board, having launched in March 2024.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37875272/how-meme-coin-sausage-is-made-according-to-crypto-vc-i-may-be-everyones-exit-liquidity?utm_campaign=partner_feed&amp;utm_source=InvestingUK&amp;utm_medium=partner_feed&amp;utm_content=TopStories">How &#8216;Meme Coin Sausage Is Made,&#8217; According To Crypto VC: &#8216;I May Be Everyone&#8217;s Exit Liquidity&#8217;</a>
Why It Matters: While meme coins have generated skyrocketing returns since the start of 2024 amid what is being called the <a href="https://www.benzinga.com/markets/cryptocurrency/24/03/37445799/welcome-to-the-memecoin-supercycle-mad-crypto-money-with-ivan">meme coin super cycle</a>, the lack of utility and increasing number of scams raise concerns in the crypto community.
A CoinGecko report highlighted the meme coin narrative as the <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38147768/crypto-q1-report-highlights-300-meme-coin-renaissance-and-major-step-for-ethereum">most profitable</a> in the year&#8217;s first quarter, with the highest returns of 1312.6% on average across its top tokens. The report adds that the meme coin narrative was 4.6 times more profitable than the next best-performing crypto narrative, real-world assets.
With the upcoming Bitcoin Halving, analysts continue to predict a bull run in Bitcoin prices until the end of the year, potentially pushing altcoins, including meme coins, even higher.
What's Next: The influence of meme coins and&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;are topics expected to be thoroughly explored at Benzinga's upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38269843/dogecoin-shiba-inu-dogwifhat-among-top-picks-for-this-researchers-meme-coin-supercycle-the">Dogecoin, Shiba Inu, Dogwifhat Among Top Picks For This Researcher&#8217;s &#8216;Meme Coin Supercycle&#8217; Thesis</a>
Image: Shutterstock

$BOME

$BONK

$BRETT

$DOGE

$FLOKI

$MEW

$PEPE

$SHIB

$WIF

Dogecoin, Shiba Inu And Who Else? How Meme Coins Have Evolved Since The Last Bitcoin Halving

Wisdom passed down through generations often serves investors well in markets. "Don't put all your eggs in one basket" is a good lesson about portfolio diversification and risk management.&nbsp;
But there's another old saying that applies to markets, at least in some situations: "One bad apple can spoil the whole bunch." Barings Bank, one of England's oldest and most influential institutions, learned this the hard way when its lack of internal controls allowed a renegade prop trader to get himself — and the firm— in hot water.
Don't Miss:&nbsp;
<ul>
<li>This prop trading firm allows traders to receive 100% of the first $25,000 per account and 90% beyond that.<a href="https://www.benzinga.com/money/apex-trader-funding"> Heres how you can get in on the profit.</a></li>
</ul>
<h2 class="wp-block-heading">Risk (Mis)management</h2>
Barings Bank was one of Britain's most renowned financial firms, with a history dating to the early 1760s. In Jules Verne's 1872 classic "Around The World In 80 Days," Barings Bank holds the £20,000 ($24,894) wager check while Phileas Fogg attempts to beat the clock in his global circumnavigation.&nbsp;
In the early 1990s, Barings Bank sought to expand its operations and hired a young hotshot trader named Nick Leeson at its Singapore office. Leeson was inexperienced but bold, and his early trading strategies raked in profits for Barings. Leeson earned Barings £2 million in 1992, specializing in <a href="https://www.benzinga.com/money/best-strategies-for-futures-trading">futures and derivatives</a>, and his success allowed his trading activity to go largely unsupervised.
Encouraged by his lack of supervision and increasingly lucrative bonuses, Leeson began to take on more risk. But he did more than execute risky trades — he began to cover up losses using so-called "error accounts," which were meant to be dummy accounts used to fix trading errors. Barings executives failed to notice the deception, and Leeson kept hiding bad trades in the error account while reporting his wins to his bosses.&nbsp;
<h2 class="wp-block-heading">Digging Deeper By Doubling Down</h2>
Barings Bank might have avoided a death sentence if Leeson had just come clean once it was apparent trouble was brewing. But like a tilting gambler, Leeson adopted a martingale system in which he doubled his wager after every losing investment. If one trade lost £200,000, he'd throw £400,000 into the next trade.&nbsp;
Additionally, Leeson began hiding increasingly larger losses in his secretive account. A £2 million negative balance in 1992 expanded to £23 million by 1993. By 1994, the account was over £208 million in the red, and Leeson was getting desperate. In a rash move, he placed a <a href="https://www.benzinga.com/money/best-futures-trading-software">futures trade</a> that would profit if volatility remained low in Japan's Nikkei 225 index. Leeson's timing could not have been worse — an earthquake struck the following day, rattling Asian markets and destroying Leeson's positions.
The scandal's aftermath was swift and brutal. Leeson left the bank with losses beyond its available capital, and his deceit earned him a criminal conviction and four years in a Singapore prison cell. Barings Bank barreled into bankruptcy and was eventually sold for a single pound to Dutch competitor ING Group. In three years, Leeson's reckless trading and subsequent fraud had turned Barings Bank from a respected institution to a defunct failure.
Prop traders often have to deal with conflicting emotions. On one hand, the most profitable traders are the ones who receive funding, but on the other, too much risk can sink a portfolio and a reputation. Prop trading isn't for the faint-hearted. But if you have an eye for trading (and the stomach to handle volatility), consider a prop trading challenge like the <a href="https://the5ers.com/bootcamp/">Bootcamp program</a> offered by The 5ers, where you can get started with $100,000 in demo capital for less than $100.
Read Next:
<ul>
<li>Find out how you can leverage up to $4,000,000 in capital with this prop trading firm &#8211;<a href="https://www.benzinga.com/money/the-5ers"> learn how</a>.&nbsp;</li>
</ul>

Barings Goes Bust: How A Single Prop Trader Took Down One Of Britain's Oldest Banks

BPTH

Bio-Path Shares Resume Trade Following Circuit Breaker Halt

Contracts

U.S. Space Force Extends Partnership With L3Harris To Enhance Space Domain Awareness With Contract Worth Up To $187M

Macro Economic Events

Politics

Economics

State Department Says The United States Has Imposed Additional Restrictions On The Delegation Of The Iranian Foreign Minister In New York For UN Meetings

Financial giants have made a conspicuous bullish move on Trade Desk. Our analysis of options history for Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) revealed 14 unusual trades.
Delving into the details, we found 78% of traders were bullish, while 21% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $820,467, and 7 were calls, valued at $516,755.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $80.0 to $140.0 for Trade Desk during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Trade Desk's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Trade Desk's substantial trades, within a strike price spectrum from $80.0 to $140.0 over the preceding 30 days.
<h3>Trade Desk Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713463463_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$7.65</td>
<td>$7.6</td>
<td>$7.6</td>
<td>$82.50</td>
<td>$594.3K</td>
<td>1.9K</td>
<td style="text-align: right;">796</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$6.8</td>
<td>$6.75</td>
<td>$6.8</td>
<td>$82.50</td>
<td>$136.0K</td>
<td>1.0K</td>
<td style="text-align: right;">710</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$6.75</td>
<td>$6.7</td>
<td>$6.75</td>
<td>$82.50</td>
<td>$135.0K</td>
<td>1.0K</td>
<td style="text-align: right;">110</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$6.75</td>
<td>$6.7</td>
<td>$6.75</td>
<td>$82.50</td>
<td>$73.5K</td>
<td>1.0K</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$49.1</td>
<td>$48.85</td>
<td>$49.1</td>
<td>$130.00</td>
<td>$54.0K</td>
<td>1</td>
<td style="text-align: right;">22</td>
</tr>
</tbody>
</table>

<h3>About Trade Desk</h3>
The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.
Having examined the options trading patterns of Trade Desk, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Trade Desk</h3>
<ul>
<li>Trading volume stands at 895,488, with TTD's price up by 0.7%, positioned at $80.69.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 20 days.</li>
</ul>
<h3>What The Experts Say On Trade Desk</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $100.0.
<ul>
<li>An analyst from Needham downgraded its action to Buy with a price target of $100. </li>
</ul>
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Trade Desk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Trade Desk's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bearish stance on Toll Brothers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with TOL, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 9 options trades for Toll Brothers.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 55%, bearish.
Out of all of the options we uncovered, 8 are puts, for a total amount of $451,815, and there was 1 call, for a total amount of $63,750.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $120.0 for Toll Brothers, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Toll Brothers stands at 405.5, with a total volume reaching 1,900.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Toll Brothers, situated within the strike price corridor from $100.0 to $120.0, throughout the last 30 days.
<h3>Toll Brothers Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713463457_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TOL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$10.2</td>
<td>$9.9</td>
<td>$9.9</td>
<td>$120.00</td>
<td>$76.4K</td>
<td style="text-align: right;">250</td>
<td style="text-align: right;">713</td>
</tr>
<tr>
<td>TOL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$10.2</td>
<td>$9.9</td>
<td>$9.9</td>
<td>$120.00</td>
<td>$76.3K</td>
<td style="text-align: right;">250</td>
<td style="text-align: right;">713</td>
</tr>
<tr>
<td>TOL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$9.7</td>
<td>$9.4</td>
<td>$9.55</td>
<td>$120.00</td>
<td>$69.9K</td>
<td style="text-align: right;">250</td>
<td style="text-align: right;">214</td>
</tr>
<tr>
<td>TOL</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$25.8</td>
<td>$25.3</td>
<td>$25.5</td>
<td>$100.00</td>
<td>$63.7K</td>
<td style="text-align: right;">561</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>TOL</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$9.5</td>
<td>$9.1</td>
<td>$9.35</td>
<td>$120.00</td>
<td>$56.1K</td>
<td style="text-align: right;">250</td>
<td style="text-align: right;">60</td>
</tr>
</tbody>
</table>

<h3>About Toll Brothers</h3>
Toll Brothers is the leading luxury homebuilder in the United States with an average sale price well above public competitors'. The company operates in over 60 markets across 24 states and caters to move-up, active-adult, and second-home buyers. Traditional homebuilding operations represent most of company's revenue. Toll Brothers also builds luxury for-sale and for-rent properties in urban centers across the U.S. It has its headquarters in Horsham, Pennsylvania.
Following our analysis of the options activities associated with Toll Brothers, we pivot to a closer look at the company's own performance.
<h3>Toll Brothers's Current Market Status</h3>
<ul>
<li>Trading volume stands at 573,889, with TOL's price up by 0.08%, positioned at $113.51.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 33 days.</li>
</ul>
<h3>What Analysts Are Saying About Toll Brothers</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $147.5.
<ul>
<li>Consistent in their evaluation, an analyst from Oppenheimer keeps a Outperform rating on Toll Brothers with a target price of $157. </li>
<li>Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for Toll Brothers, targeting a price of $138. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Toll Brothers options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Decoding Toll Brothers's Options Activity: What's the Big Picture?

Financial giants have made a conspicuous bearish move on B. Riley Financial. Our analysis of options history for B. Riley Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RILY#NASDAQ">RILY</a>) revealed 9 unusual trades.
Delving into the details, we found 11% of traders were bullish, while 88% showed bearish tendencies. Out of all the trades we spotted, 7 were puts, with a value of $267,455, and 2 were calls, valued at $60,017.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $20.0 to $25.0 for B. Riley Financial over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in B. Riley Financial's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to B. Riley Financial's substantial trades, within a strike price spectrum from $20.0 to $25.0 over the preceding 30 days.
<h3>B. Riley Financial 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713463451_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RILY</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$3.5</td>
<td>$3.2</td>
<td>$3.31</td>
<td>$20.00</td>
<td>$76.1K</td>
<td>3.1K</td>
<td style="text-align: right;">51</td>
</tr>
<tr>
<td>RILY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$1.65</td>
<td>$1.45</td>
<td>$1.65</td>
<td>$21.00</td>
<td>$37.2K</td>
<td>140</td>
<td style="text-align: right;">255</td>
</tr>
<tr>
<td>RILY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$1.7</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$21.00</td>
<td>$35.2K</td>
<td>140</td>
<td style="text-align: right;">255</td>
</tr>
<tr>
<td>RILY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$3.4</td>
<td>$3.1</td>
<td>$3.2</td>
<td>$20.00</td>
<td>$32.0K</td>
<td>762</td>
<td style="text-align: right;">30</td>
</tr>
<tr>
<td>RILY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$2.9</td>
<td>$2.4</td>
<td>$2.45</td>
<td>$22.00</td>
<td>$31.3K</td>
<td>383</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>

<h3>About B. Riley Financial</h3>
B. Riley Financial Inc is a diversified financial services company. The company through its subsidiaries offers investment banking and financial services to corporate, institutional and high net worth clients and also asset disposition, valuation and appraisal and capital advisory services to retail, wholesale, institutional, lenders, capital providers, private equity investors, and professional services firms in United States, Canada, and Europe. It also provides internet access and subscription services. The reportable operating segments of the company include Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer segment.
In light of the recent options history for B. Riley Financial, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Current Position of B. Riley Financial</h3>
<ul>
<li>Trading volume stands at 192,897, with RILY's price down by 0.0%, positioned at $20.46.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 14 days.</li>
</ul>
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for B. Riley Financial with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

RILY

Check Out What Whales Are Doing With RILY

Needham analyst Kyle Peterson reiterates Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) with a Buy and maintains $305 price target.

Needham Reiterates Buy on Equifax, Maintains $305 Price Target

In the last three months, 5 analysts have published ratings on IGM Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>), offering a diverse range of perspectives from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for IGM Biosciences, presenting an average target of $17.2, a high estimate of $21.00, and a low estimate of $12.00. Observing a 115.0% increase, the current average has risen from the previous average price target of $8.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1713463344_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
A comprehensive examination of how financial experts perceive IGM Biosciences is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Driscoll</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$20.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$21.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to IGM Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of IGM Biosciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of IGM Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into IGM Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/IGMS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on IGM Biosciences analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into IGM Biosciences's Background</h2>
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
<h3>Financial Milestones: IGM Biosciences's Journey</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: IGM Biosciences's remarkable performance in 3 months is evident. As of 31 December, 2023, the company achieved an impressive revenue growth rate of 75.0%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: IGM Biosciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -9323.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): IGM Biosciences's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -26.56%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): IGM Biosciences's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -13.52%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: IGM Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.2.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

IGMS

What 5 Analyst Ratings Have To Say About IGM Biosciences

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Rithm Capital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RITM#NYSE">RITM</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $12.14, along with a high estimate of $13.00 and a low estimate of $11.00. This upward trend is apparent, with the current average reflecting a 6.68% increase from the previous average price target of $11.38.
<img src="https://www.benzinga.com/files/images/story/2024/1713463317_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Rithm Capital. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trevor Cranston</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$11.00</td>
<td>-</td>
</tr>
<tr>
<td>Bose George</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$12.00</td>
<td>$11.50</td>
</tr>
<tr>
<td>Kenneth Lee</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Kevin Heal</td>
<td>Argus Research</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Jay McCanless</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$13.00</td>
<td>-</td>
</tr>
<tr>
<td>Matthew Erdner</td>
<td>JonesTrading</td>
<td>Raises</td>
<td>Buy</td>
<td>$12.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Matt Howlett</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Rithm Capital. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rithm Capital compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Rithm Capital's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Rithm Capital's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RITM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Rithm Capital analyst ratings.</a>
<h2>Unveiling the Story Behind Rithm Capital</h2>
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company's mission is to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Rithm Capital's investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans.
<h3>Breaking Down Rithm Capital's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Negative Revenue Trend: Examining Rithm Capital's financials over 3 months reveals challenges. As of 31 December, 2023, the company experienced a decline of approximately -21.17% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Rithm Capital's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -26.07%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Rithm Capital's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -1.5%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Rithm Capital's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.25%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Rithm Capital's debt-to-equity ratio stands notably higher than the industry average, reaching 4.19. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RITM

Expert Ratings For Rithm Capital

Across the recent three months, 5 analysts have shared their insights on Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $38.2, along with a high estimate of $51.00 and a low estimate of $24.00. This current average has increased by 48.35% from the previous average price target of $25.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1713463287_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Dianthus Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Steven Seedhouse</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$51.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Maury Raycroft</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$39.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Alex Thompson</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$44.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dianthus Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dianthus Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Dianthus Therapeutics's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Dianthus Therapeutics's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/DNTH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Dianthus Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Dianthus Therapeutics: A Closer Look</h2>
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
<h3>Dianthus Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Decline in Revenue: Over the 3 months period, Dianthus Therapeutics faced challenges, resulting in a decline of approximately -61.11% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dianthus Therapeutics's net margin is impressive, surpassing industry averages. With a net margin of -2311.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Dianthus Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -6.08%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Dianthus Therapeutics's ROA excels beyond industry benchmarks, reaching -5.68%. This signifies efficient management of assets and strong financial health.
Debt Management: Dianthus Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.0.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DNTH

What 5 Analyst Ratings Have To Say About Dianthus Therapeutics

Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) has outperformed the market over the past 15 years by 8.83% on an annualized basis producing an average annual return of 21.22%. Currently, Adobe has a market capitalization of $212.35 billion. 
Buying $1000 In ADBE: If an investor had bought $1000 of ADBE stock 15 years ago, it would be worth $19,362.34 today based on a price of $473.99 for ADBE at the time of writing.
<h3>Adobe's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713463281_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADBE

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $19,000 Today

The 10 rating InvestorsObserver gives to Baudax Bio Inc (BXRX)  stock puts it near the bottom of the Healthcare sector.In addition to scoring higher than 6 percent of stocks in the Healthcare sector, BXRXâ€&#x2122;s 10 overall rating means the stock scores better than 10 of all stocks. BXRX has an Overall Score of 10. Find out what

Should You Add Baudax Bio Inc (BXRX) Stock to Your Portfolio Wednesday?

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Afya (AFYA – Research Report), Alkermes (ALKS – Re...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Afya (AFYA), Alkermes (ALKS) and Baudax Bio (BXRX)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We&rsquo;re starting off the day with a breakdown of all the biggest pre-market stock movers traders need to know about on Friday!
Moving stocks this morning are a reverse split, a government order, earnings reports, and more.
Let&rsquo;s get into that news below!

<h2>Pre-Market Stock Movers: 10 Top Gainers</h2>
<ol>
<li>INVO Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is rocketing more than 2,227%, or at least it looks to be, but it&rsquo;s actually undergoing a <a href="https://www.prnewswire.com/news-releases/invo-announces-a-120-reverse-stock-split-effective-pre-market-opening-on-july-28-2023-301887437.html">one-for-20 reverse stock split</a>.</li>
<li>SIGA Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/siga-stock-quote/">SIGA</a>) shares are soaring over 31% after announcing a <a href="https://investor.siga.com/news-releases/news-release-details/siga-announces-us-government-procurement-orders-approximately">$138 million government order</a>.</li>
<li>Unique Fabricating (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ufab-stock-quote/">UFAB</a>) stock is surging more than 30% alongside heavy pre-market trading.</li>
<li>Greenbrook TMS (NASDAQ:<a href="https://investorplace.com/stock-quotes/gbnh-stock-quote/">GBNH</a>) shares are rising over 25% as they also see heavy early morning trading.</li>
<li>Inpixon (NASDAQ:<a href="https://investorplace.com/stock-quotes/inpx-stock-quote/">INPX</a>) stock is gaining more than 21% with strong trading activity this morning.</li>
<li>Homology Medicines (NASDAQ:<a href="https://investorplace.com/stock-quotes/fixx-stock-quote/">FIXX</a>) shares are climbing over 19% after announcing <a href="https://www.nasdaq.com/press-release/homology-medicines-announces-encouraging-initial-data-from-first-dose-level-in-the">positive data from a trial</a>.</li>
<li>Baudax Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/bxrx-stock-quote/">BXRX</a>) stock is increasing more than 17% on Friday.</li>
<li>Creative Medical Technology&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/celz-stock-quote/">CELZ</a>) shares are getting an over 17% boost without anything to report this morning.</li>
<li>Coursera (NYSE:<a href="https://investorplace.com/stock-quotes/cour-stock-quote/">COUR</a>) stock is jumping more than 15% with the release of its <a href="https://www.marketwatch.com/story/coursera-shares-rise-10-after-company-reports-2q-results-16d99ef1">Q2 earnings report</a>.</li>
<li>Aeye (NASDAQ:<a href="https://investorplace.com/stock-quotes/lidr-stock-quote/">LIDR</a>) shares are up over 14% on Friday morning.</li>
</ol>
<h2>10 Top Losers</h2>
<ol>
<li>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/">TNXP</a>) stock is plummeting more than 37% after announcing a <a href="https://ir.tonixpharma.com/news-events/press-releases/detail/1408/tonix-pharmaceuticals-announces-proposed-public-offering">proposed public offering</a>.</li>
<li>Sleep Number (NASDAQ:<a href="https://investorplace.com/stock-quotes/snbr-stock-quote/">SNBR</a>) shares are crashing close to 27% after releasing its <a href="https://www.nasdaq.com/press-release/sleep-number-announces-second-quarter-2023-results-2023-07-27">latest earnings report</a> and appointing <a href="https://www.nasdaq.com/press-release/sleep-number-appoints-francis-lee-to-executive-vice-president-and-chief-financial">a new Chief Financial Officer</a>.</li>
<li>Greenidge Generation (NASDAQ:<a href="https://investorplace.com/stock-quotes/gree-stock-quote/">GREE</a>) stock is diving over 19% despite a lack of news today.</li>
<li>Enphase Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/enph-stock-quote/">ENPH</a>) shares are taking a more than 16% beating after <a href="https://finance.yahoo.com/news/enphase-energy-reports-financial-results-200500066.html">releasing its Q2 earnings report</a>.</li>
<li>Bellerophon Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/blph-stock-quote/">BLPH</a>) stock is tumbling over 15% <a href="https://investorplace.com/2023/07/why-is-bellerophon-therapeutics-blph-stock-down-34-today/">alongside recent negative activity</a>.</li>
<li>Mallinckrodt (NYSEMKT:<a href="https://investorplace.com/stock-quotes/mnk-stock-quote/">MNK</a>) shares are sliding more than 15% without any clear news this morning.</li>
<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) stock is decreasing over 14% on Friday after a recent rally.</li>
<li>Avenue Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/atxi-stock-quote/">ATXI</a>) shares are slipping more than 14% despite a <a href="https://www.nasdaq.com/press-release/avenue-therapeutics-announces-first-patient-dosed-in-phase-1b-2a-clinical-trial-of">recent clinical update</a>.</li>
<li>Titan Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ttnp-stock-quote/">TTNP</a>) stock is dipping over 13% following <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317643912&amp;type=PDF&amp;symbol=TTNP&amp;cdn=32a29d4989b051227e45a1208a1d0da9&amp;companyName=Titan+Pharmaceuticals+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-07-28">an asset sale and other news</a>.</li>
<li>Femasys (NASDAQ:<a href="https://investorplace.com/stock-quotes/femy-stock-quote/">FEMY</a>) shares close out our pre-market stock movers down more than 12% after <a href="https://www.marketwatch.com/story/femasys-shares-double-after-notice-of-allowance-for-u-s-patent-3e6bce56">rallying yesterday on patent news</a>.</li>
</ol>
On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
<ul>
<li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT752258">The #1 AI Name for 2023 Could Be About to Ignite This $20.6 Trillion Wealth Shift</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT752256">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
<li>
						<a href="https://investorplace.com/2022/06/this-could-be-the-best-deal-in-the-history-of-independent-investing-research/?cid=MKT638063&amp;eid=MKT752248">The $1 Investment You MUST Take Advantage of Right Now</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT752254">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
</ul>
<div>
<div>
<div></div>
<div></div>
</div>
</div>
The post <a href="https://investorplace.com/2023/07/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-july-28th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Baudax Bio GAAP EPS of -$1.49 beats by $0.55

Baudax Bio announces $1.9M registered direct offering priced ATM

Noble Financial analyst Gregory Aurand maintained a Hold rating on Baudax Bio (BXRX – Research Report) today. The company's shares closed yesterday...

Noble Financial Remains a Hold on Baudax Bio (BXRX)

Baudax Bio files to sell 15M shares of common stock for holders.

Baudax Bio Inc (BXRX) stock has fallen -93.15% over the last 12 months, and the average rating from Wall Street analysts is a Hold. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives BXRX stock a score of  3 out of a possible 100. That rank is primarily influenced by a short-term technical score of 3. BXRX's rank also i

Is Baudax Bio Inc (BXRX) Stock Worth a Buy Thursday?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
As the market attempted to recover from a recent series of disappointing performances, biotechnology firm Baudax Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/bxrx-stock-quote/">BXRX</a>) represented a dramatic winner. Earlier Thursday morning, management disclosed that the U.S. Food and Drug Administration (FDA) granted its lead clinical candidate orphan drug designation. Though encouraging, BXRX stock still has a wall of worry to climb.
According to the accompanying <a href="https://finance.yahoo.com/news/baudax-bio-announces-orphan-drug-120000606.html">press release</a>, the FDA granted the orphan drug status to the drug candidate TI-168 for the treatment of Hemophilia A with inhibitors. This therapeutic represents Baudax&rsquo;s next-generation, FVIII-specific T-cell receptor therapy utilizing human regulatory T cells (Tregs). FVIII refers to the <a href="https://pubmed.ncbi.nlm.nih.gov/6424437/">protein that is deficient or defective</a> in patients with classical hemophilia.
Per the statement, the FDA&rsquo;s Office of Orphan Products Development grants orphan status for drugs designed for conditions affecting fewer than 200,000 people in the U.S. Fundamentally, the designation provides several advantages to drug developers, including the potential for market exclusivity for seven years following FDA approval.
In addition, orphan drugs feature financial benefits such as tax credits for qualifying clinical trials and reduced annual product feels. Therefore, it&rsquo;s a huge moment for the biotech, explaining the massive leap in BXRX stock. Still, it&rsquo;s just one part of the puzzle.

<h2>BXRX Stock Faces a Credibility Crisis</h2>
Another key highlight regarding the aforementioned press release is the FDA clearance for Baudax&rsquo;s investigational new drug (IND) application. As a result of the clearance, management believes it can activate the Phase 1/2a clinical trial of TI-168 for the treatment of hemophilia A with inhibitors with a modest initial budget. As well, it opens the door to advance the therapy to further clinical investigation in early 2024.
While BXRX stock managed to almost double for the day, it&rsquo;s also important to consider the broader context. First, at a price of roughly 53 cents at time of writing, prospective investors would be absorbing a significant risk. As well, the 52-week range for shares goes from 30 cents to $12.24. In the trailing one-year period, Baudax lost almost 95% of market value.
Another glaring headwind moving against BXRX stock is the poor financials. According to investment data aggregator Gurufocus, Baudax prints a <a href="https://www.gurufocus.com/stock/BXRX/summary?search=bxrx">cash-to-debt ratio of 0.16x</a>, worse than 92.43% of the biotech industry. In addition, the Altman Z-Score of -121.46 symbolizes an enterprise in deep distress.
<h2>Why It Matters</h2>
According to TipRanks, <a href="https://www.tipranks.com/stocks/bxrx/forecast">only one analyst</a> from Noble Financial covers BXRX stock, with an unconvincing no-price &ldquo;hold&rdquo; rating. However, it&rsquo;s also fair to point out that all of the <a href="https://fintel.io/sn/us/bxrx">insider transactions</a> for Baudax represent purchases, with the last buy coming in December 2022.
On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks:&#8239;With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;InvestorPlace.com&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.
Read More:&#8239;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash;&nbsp;How to Profit Without Getting Scammed</a>
On the date of publication, Josh Enomoto did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines</a>.
<div>
A former senior business analyst for Sony Electronics, Josh Enomoto has helped broker major contracts with Fortune Global 500 companies. Over the past several years, he has delivered unique, critical insights for the investment markets, as well as various other industries including legal, construction management, and healthcare. Tweet him at @EnomotoMedia.
</div>
<h3>More From InvestorPlace</h3>
<ul>
<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766410">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766412">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766528">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
</ul>
<div>
<div>
<div></div>
<div></div>
</div>
</div>
The post <a href="https://investorplace.com/2023/09/why-is-baudax-bio-bxrx-stock-up-75-today/">Why Is Baudax Bio (BXRX) Stock Up 75% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Baudax Bio (BXRX) Stock Up 75% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time for a dive into the biggest pre-market stock movers as we check out what&rsquo;s happening on Friday!
Moving stocks this morning are public offerings, new agreements, earnings and more.
Let&rsquo;s get into that news down below!

<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>
<ol>
<li>Blue Apron (NASDAQ:<a href="https://investorplace.com/stock-quotes/aprn-stock-quote/">APRN</a>) stock is rocketing more than 130% on <a href="https://www.wsj.com/business/deals/meal-kit-maker-blue-apron-to-be-sold-d40955f9">reports of an acquisition deal</a>.</li>
<li>OpGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/opgn-stock-quote/">OPGN</a>) shares are soaring over 108% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317774881&amp;type=PDF&amp;symbol=OPGN&amp;cdn=d633ee6bfb227259668569c3ed0858d4&amp;companyName=OpGen+Inc.&amp;formType=RW&amp;formDescription=Registration+Withdrawal+Request&amp;dateFiled=2023-09-28">withdrawing a public stock offering</a>.</li>
<li>Novo Integrated Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvos-stock-quote/">NVOS</a>) stock is surging 88% after signing a <a href="https://www.businesswire.com/news/home/20230928913437/en/Novo-Integrated-Sciences-Signs-Master-Collateral-Transfer-Agreement">$1 billion master collateral transfer agreement</a>.</li>
<li>RVL Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/rvlp-stock-quote/">RVLP</a>) shares are rising more than 63% alongside heavy pre-market trading.</li>
<li>Femasys (NASDAQ:<a href="https://investorplace.com/stock-quotes/femy-stock-quote/">FEMY</a>) stock is gaining close to 29% as it continues a rally that <a href="https://investorplace.com/2023/09/why-is-femasys-femy-stock-up-181-today/">started earlier this week</a>.</li>
<li>Brooge Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/brog-stock-quote/">BROG</a>) shares are increasing over 17% without any clear news this morning.</li>
<li>A2Z Smart Techs (NASDAQ:<a href="https://investorplace.com/stock-quotes/az-stock-quote/">AZ</a>) stock is climbing more than 14% despite a lack of news today.</li>
<li>T2 Biosystems (NASDAQ:<a href="https://investorplace.com/stock-quotes/ttoo-stock-quote/">TTOO</a>) shares are getting an over 12% boost after <a href="https://investorplace.com/2023/09/cr-group-just-sold-more-shares-of-t2-biosystems-ttoo-stock/">slipping earlier this week</a>.</li>
<li>OLB Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/olb-stock-quote/">OLB</a>) stock is jumping almost 10% on Friday morning.</li>
<li>Solowin (NASDAQ:<a href="https://investorplace.com/stock-quotes/swin-stock-quote/">SWIN</a>) shares are up over 9% this morning.</li>
</ol>
<h2>10 Top Losers</h2>
<ol>
<li>Glimpse (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrar-stock-quote/">VRAR</a>) stock is plummeting more than 43% with the release of its <a href="https://finance.yahoo.com/news/glimpse-group-reports-fiscal-2023-200500695.html">latest earnings report</a>.</li>
<li>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/">TNXP</a>) shares are diving over 32% after <a href="https://www.nasdaq.com/press-release/tonix-pharmaceuticals-announces-pricing-of-%244.5-million-public-offering-2023-09-28">pricing a public stock offering</a>.</li>
<li>Vaccinex (NASDAQ:<a href="https://investorplace.com/stock-quotes/vcnx-stock-quote/">VCNX</a>) stock is tumbling more than 30% as it also <a href="https://www.nasdaq.com/press-release/vaccinex-announces-pricing-of-%249.6-million-public-offering-2023-09-28">priced a public offering</a> for its shares.</li>
<li>Dynatronics (NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/">DYNT</a>) shares are taking an over 30% beating after <a href="https://finance.yahoo.com/news/dynatronics-corporation-dynt-reports-q4-141502844.html">releasing its fiscal Q4 earnings report</a>.</li>
<li>Baudax Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/bxrx-stock-quote/">BXRX</a>) stock is dropping more than 20% as it <a href="https://www.marketwatch.com/story/baudax-bio-shares-double-after-orphan-drug-designation-for-ti-168-d34b6923">retreats following a rally yesterday</a>.</li>
<li>Bionomics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bnox-stock-quote/">BNOX</a>) shares are sliding over 16% after a massive rally yesterday on <a href="https://investorplace.com/2023/09/why-is-bionomics-bnox-stock-up-347-today/">clinical trial results</a>.</li>
<li>SIGNA Sports United (NYSE:<a href="https://investorplace.com/stock-quotes/ssu-stock-quote/">SSU</a>) stock is decreasing more than 15% on Friday morning.</li>
<li>Hub Cyber Security (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/">HUBC</a>) shares are slipping over 14% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317775794&amp;type=PDF&amp;symbol=HUBC&amp;cdn=b7ed90f52e02aaa4ad9ea6cd9aacb6e5&amp;companyName=Hub+Cyber+Security+Ltd.&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2023-09-29">announcing a shareholder meeting</a>.</li>
<li>Essential Props Realty (NYSE:<a href="https://investorplace.com/stock-quotes/eprt-stock-quote/">EPRT</a>) stock is dipping more than 14% today.</li>
<li>Capstone Green Energy (NASDAQ:<a href="https://investorplace.com/stock-quotes/cgrn-stock-quote/">CGRN</a>) shares close out our pre-market stock movers down over 14% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=317773315&amp;type=PDF&amp;symbol=CGRN&amp;cdn=2e733aeab3deae0b7210077f8795258f&amp;companyName=Capstone+Green+Energy+Corporation&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2023-09-28">after a Chapter 11 filing</a>.</li>
</ol>
On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
<ul>
<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766410">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766412">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT766528">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
</ul>
<div>
<div>
<div></div>
<div></div>
</div>
</div>
The post <a href="https://investorplace.com/2023/09/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-friday-sept-29th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AFYA

ALKS

APRN

ATXI

BLPH

BNOX

BROG

BXRX

CELZ

CGRN

COUR

DYNT

ENPH

EPRT

FEMY

FIXX

GBNH

GREE

HUBC

INPX

INVO

LIDR

NVOS

OPGN

RVLP

SIGA

SNBR

SWIN

TNXP

TTNP

TTOO

UFAB

VCNX

VINE

VRAR

Press Releases

Baudax Bio Announces Date of Reconvened Annual Meeting

Health Care

Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000

Baudax Bio Acquires TeraImmune, Inc.

Earnings

Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Dividends

Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock

Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference

Small Cap

Opinion

Thinking about buying stock in Arch Capital Group, Oncolytics Biotech, Baudax Bio, Femasys, or Traction Uranium?

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors